Gilead terminates Phase II/III study for ulcerative colitis antibody
pharmafile | September 22, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Gilead, ulcerative colitis
Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative colitis after the drug failed to show sufficient efficacy.
The decision was reached after the Data Monitoring Committee reviewed the experiences of the first 150 of a planned 1,600 trial participants. The committee recommended the termination of the study due to it meeting pre-specified futility and efficacy criteria.
Gilead has not given up hopes on the drug and is currently pursuing Phase III studies for the antibody in the treatment of gastric cancer and a combination trial with nivolumab. The company also plans to keep pushing for developments in the treatment of Crohn’s disease, cystic fibrosis and rheumatoid arthritis.
Gilead’s shares had slightly fallen in after-market trading.
Matt Fellows
Related Content
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …
Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results …
Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh …